iBio, Inc. (IBIO) Receives Additional Canadian Patent Related to iBioModulator

November 21, 2016 8:35 AM EST
Get Alerts IBIO Hot Sheet
Trade IBIO Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

iBio, Inc. (NYSE: IBIO) announced the issue of a new Canadian patent in the company's iBioModulator thermostable immunomodulator protein portfolio. The new patent, serial number 2692933, is entitled "Yersinia Pestis Antigens, Vaccine Compositions and Related Methods" and issued October 18, 2016. The patent includes claims covering plague antigens fused to the Company's iBioModulatorâ„¢ thermostable immunomodulator, as well as vaccine compositions and a method for producing the antigen.

The new Canadian patent joins iBio's other patents in the Plague Vaccine family in the US (8,404,252, 8,945,580), and also in international markets of interest to iBio and its clients, including Germany, France, Ireland, and United Kingdom. Plague is considered a potential bioterrorism weapon.

"This is an important extension of intellectual property protection for our commercial technology platform," said Wayne Fitzmaurice, Ph.D., iBio's Vice President, Intellectual Property. "Use of our technology for the development and production of superior Plague vaccines should enable governments to better protect their citizens from the threat of weaponized plague. The broader iBioModulator patent family comprises seven US patents and multiple foreign patents. We see numerous applications of the iBioModulator technology for both therapeutic and preventive vaccines."

There is no plague vaccine currently approved for use in the U.S. Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, such vaccines were not effective against pneumonic plague. By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced using iBio's proprietary technology in green plants, provided full protection of non-human primates against aerosolized Y. pestis (pneumonic plague).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Litigation

Related Entities

Earnings

Add Your Comment